Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.

Molecular cancer therapeutics - 5 Jul 2023

Albers Joachim, Friese-Hamim Manja, Clark Anderson, Schadt Oliver, Walter-Bausch Gina, Stroh Christopher, Johne Andreas, Karachaliou Niki, Blaukat Andree

Abstract excerpt

The mesenchymal-epithelial transition factor (MET) proto-oncogene encodes the MET receptor tyrosine kinase. MET aberrations drive tumorigenesis in several cancer types through a variety of molecular mechanisms, including MET mutations, gene amplification, rearrangement, and overexpression. Therefore, MET is a therapeutic target and the selective type Ib MET inhibitor, tepotinib, was designed to potently inhibit...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 36999986
DOI: 10.1158/1535-7163.MCT-22-0537
PMCID: PMC10320478

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.PMID 36999986Read ↗

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.Semantic proximity Read ↗

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.Semantic proximity Read ↗

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?Semantic proximity Read ↗

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping MutationSemantic proximity Read ↗

Tepotinib hydrochloride for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Tepotinib in patients with MET exon 14 skipping non-small cell lung cancerSemantic proximity Read ↗

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.Semantic proximity Read ↗

Targeting un-MET needs in advanced non-small cell lung cancer.Semantic proximity Read ↗

Targeting MET Dysregulation in CancerSemantic proximity Read ↗

MET-dependent solid tumours - molecular diagnosis and targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.